跳至主要内容
临床试验/NCT00293280
NCT00293280已完成2 期

Phase II Study of CCNU (Lomustine) in Patients With Advanced Non-Small Cell Lung Cancer and Aberrant Hypermethylation of the MGMT Gene

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins2 个研究点 分布在 1 个国家目标入组 42 人开始时间: 2005年7月最近更新:
适应症
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
42
试验地点
2
主要终点
Response rate

研究概览

简要总结

RATIONALE: Drugs used in chemotherapy, such as lomustine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.

PURPOSE: This phase II trial is studying how well lomustine works in treating patients with stage III or stage IV non-small cell lung cancer.

详细描述

OBJECTIVES:

Primary

  • Evaluate the response rate to lomustine in patients with stage IIIB or IV non-small cell lung cancer with aberrant methylation of the MGMT gene.
  • Determine whether the response rate in these patients is significantly greater than that of the historical control.

Secondary

  • Collect preliminary data on toxicity, disease stabilization, time to disease progression, and overall survival.

研究设计

研究类型
Interventional
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Response rate

次要结局

  • Association between clinical outcome and immunohistochemical staining
  • Toxicity
  • Disease stabilization
  • Overall survival
  • Time to disease progression

研究者

研究点 (2)

Loading locations...

相似试验